Eisai Co Ltd

Sopa Images | Lightrocket | Getty ImagesPfizer's twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on…

Eisai on Wednesday said an injectable version of the Alzheimer's drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient option for administering the antibody treatment. …

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.Cristina Arias | Cover | Getty ImagesEli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer's…

The Alzheimer's drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | via ReutersMedicare has agreed to pay for the Alzheimer's treatment Leqembi, a major turning point for patients who are…

Jay Reinstein, who suffers from Alzheimer's, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty ImagesSales of…

The Food and Drug Administration on Thursday approved the Alzheimer's treatment Leqembi, a pivotal decision that will expand access to the expensive drug for older Americans.Medicare announced shortly after the FDA approval that it is now…

A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer's drug Leqembi, made by Eisai and Biogen, should receive full approval.The FDA is not required to follow…

Sen. Bernie Sanders (I-VT) arrives to the U.S. Capitol Building on June 01, 2023 in Washington, DC.Anna Moneymaker | Getty ImagesSen. Bernie Sanders on Wednesday called on the U.S. Health and Human Services Department to take action to…

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | ReutersThe new Alzheimer's antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research…

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | via ReutersDemocratic and Republican attorneys general in nearly half of U.S. states are calling on Medicare to provide…